Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
ZIOPHARM Oncology
Develops risk-sensitive in-licensed cancer drugs to address unmet medical needs
Boston, MA
NASDAQ: ZIOP
Contact:
Scott Barry
Related News
Ziopharm Adds $50M, Pushing Internal, Partnered Programs
ZIOPHARM and Solasia Pharma Announce License and Collaboration Agreement for Darinaparsin in Asia
ZIOPHARM Receives Positive Opinion for Orphan Drug Designation for Darinaparsin from European Medicines Agency
ZIOPHARM Oncology and Intrexon Announce Worldwide Partnership for Synthetic Biology DNA-based Oncology Therapeutics